LOS ANGELES, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces the dosing of its first two patients in its Phase 1 trial testing a combination therapy for its lead therapeutic candidate ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer.

2024年1月16日，洛杉矶（环球通讯社）--Kairos Pharma，Ltd.，一家临床阶段的生物制药公司，开发旨在逆转癌症耐药性和免疫抑制的癌症治疗药物，宣布其第一阶段试验中的前两名患者的剂量，该试验测试了其主要治疗候选药物ENV105与osimertinib联合治疗非小细胞肺癌的联合疗法。

Kairos Pharma CEO John Yu stated, “The initiation of this trial speaks to the dedication of the Kairos team to execute on its goals to develop therapies for today’s unmet medical needs.” The primary objective of this open-label trial is to evaluate the safety and tolerability of the combination therapy.

Kairos Pharma首席执行官John Yu表示：“这项试验的启动表明，Kairos团队致力于实现其目标，为当今未满足的医疗需求开发治疗方法。”这项开放标签试验的主要目标是评估联合治疗的安全性和耐受性。

The trial aims to enroll 60 patients who have developed clear resistance to osimertinib, as well as those who have shown partial sensitivity to the drug. Lung cancer patients with epidermal growth factor receptor (EGFR) mutations typically receive EGFR-antagonists like osimertinib as a first line treatment.

该试验旨在招募60名对osimertinib产生明显耐药性的患者，以及对该药物表现出部分敏感性的患者。具有表皮生长因子受体（EGFR）突变的肺癌患者通常接受EGFR拮抗剂如osimertinib作为一线治疗。

While effective initially, patients on osimertinib therapy eventually develop resistance. ENV105 is a first-in-class biologic developed to enhance the sensitivity of EGFR-driven lung cancer patients to EGFR-antagonists. Dr. Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, added, “It made sense to use ENV105 for such patients since blocking EGFR induced the target of ENV105, CD105, a known mediator of tumor progression.” About Kairos PharmaBased in Los Angeles, California, Kairos Pharma, Ltd.

虽然最初有效，但接受osimertinib治疗的患者最终会产生耐药性。ENV105是一种一流的生物制剂，用于增强EGFR驱动的肺癌患者对EGFR拮抗剂的敏感性。Kairos Pharma首席科学官Neil Bhowmick博士补充说，“对于此类患者使用ENV105是有意义的，因为阻断EGFR诱导了ENV105的靶标，CD105是一种已知的肿瘤进展介质。”关于位于加利福尼亚州洛杉矶的Kairos Pharma，Kairos Pharma，Ltd。

is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of cutting-edge oncology therapeutics that reverse the inhibitory effects of cancer on the immune system. The Company is advancing its portfolio of innovativ.

是一家临床阶段的生物制药公司，专注于开发多元化的尖端肿瘤治疗药物，以逆转癌症对免疫系统的抑制作用。该公司正在推进其创新投资组合。